Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
Rhea-AI Summary
Aclarion (Nasdaq: ACON, ACONW) announced issuance of U.S. Patent #12,601,803 on April 16, 2026 for a machine learning–based system to analyze magnetic resonance spectroscopy (MRS) data. The patent covers AI-driven model training, automated data quality controls, and biomarker extraction within the cloud-based Nociscan platform.
The filing expands Aclarion's intellectual property to 64 issued and pending patents worldwide and is described as enabling scale, faster reports, reduced manual reviews, and more consistent outputs across imaging systems.
AI-generated analysis. Not financial advice.
Positive
- Issued U.S. Patent #12,601,803 covering AI analysis of MRS data
- Intellectual property portfolio expanded to 64 issued and pending patents worldwide
- Nociscan patent protects AI-based automated data quality controls and biomarker extraction
- Company cites potential for faster reports, reduced manual reviews, and scalable automation
Negative
- None.
News Market Reaction – ACON
On the day this news was published, ACON gained 3.75%, reflecting a moderate positive market reaction. Argus tracked a peak move of +16.5% during that session. Argus tracked a trough of -8.1% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $264K to the company's valuation, bringing the market cap to $7.30M at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, ACON’s modest 0.95% gain contrasts with mixed peers: WORX up 8.82%, BFRG down 7.22%, VSEE down 2.17%, while POAI and DRIO were roughly flat. Movements do not point to a unified sector trend.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | AI innovation award | Positive | -1.3% | Recognition of Nociscan’s AI innovation in clinical decision support. |
| Sep 27 | AI clinical study | Positive | +0.4% | Study highlighting Nociscan AI’s role in understanding Modic changes. |
| Sep 12 | AI tech update | Positive | +15.4% | Corporate update on AI milestones, coverage, partnerships and studies. |
| Aug 21 | AI trial launch | Positive | -0.6% | Launch of CLUE trial to measure Nociscan AI’s impact on surgery plans. |
AI-related headlines have produced mixed reactions: two positive and two negative moves, suggesting investors respond selectively to AI news quality and perceived commercial impact.
Recent history shows Aclarion steadily building its AI-driven Nociscan platform and clinical evidence base. Prior AI-tagged releases included an innovation award, study data on Modic changes, a broad corporate AI milestone update, and the CLUE trial launch. Market reactions ranged from declines to a 15.38% gain, indicating that while AI advances can be catalysts, investor response has varied depending on perceived strategic and commercial significance.
Historical Comparison
Across past AI-tagged announcements, ACON saw an average move of about 3.48%, with both strong rallies and selloffs, showing AI news has been a meaningful but unpredictable catalyst.
AI-tagged history shows progression from launching trials (CLUE), to broad Nociscan AI corporate milestones, to clinical study data and external innovation recognition. The new AI-focused patent extends this arc by reinforcing IP around the core machine learning and biomarker engine.
Market Pulse Summary
This announcement adds a new U.S. patent around Aclarion’s machine learning platform for chronic low back pain, expanding an IP estate of 64 issued and pending patents. It reinforces the Nociscan strategy, supported by clinical data citing up to 97% surgical success and a large pain market highlighted at $134.5 billion annually in the U.S. Investors may watch how this IP strengthens commercialization, reimbursement progress, and clinical adoption trends.
Key Terms
magnetic resonance spectroscopy medical
machine learning technical
biomarkers medical
signal-to-noise ratio technical
spectral artifacts technical
AI-generated analysis. Not financial advice.
- Patent covers use of AI in workflows of future products to accelerate company’s ability to scale and enhance already strong gross margins
- Expands intellectual property portfolio to 64 issued and pending patents worldwide, strengthening long-term competitive moat
BROOMFIELD, Colo., April 16, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain,” covering its machine learning–based platform for analyzing magnetic resonance spectroscopy (MRS) data.
Aclarion’s cloud-based platform, Nociscan, converts complex MRS spectral data into clinically actionable insights to help physicians distinguish between painful and non-painful discs in the spine. The newly issued patent strengthens Aclarion’s ability to scale by protecting its use of AI in future versions of the platform to further automate biomarker identification, accelerate report generation and reduce manual quality reviews.
“This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice,” said Brent Ness, Chief Executive Officer of Aclarion. “By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.”
The patent covers machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized classifications associated with pain-related conditions. Importantly, the patent also covers AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts. This capability will enable consistent, reproducible outputs across imaging systems and sites and represents a key step toward broader clinical adoption.
The patent further expands Aclarion’s intellectual property portfolio, with 64 issued and pending patents worldwide, and underscores its strategy to build a differentiated, software-driven platform in the large and underserved chronic low back pain market. Chronic low back pain is a significant global healthcare challenge, affecting approximately 266 million people worldwide. When used alongside other diagnostic tools, clinical data has demonstrated up to a
To read the patent, click here.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding Aclarion Highlights Growing Adoption of Nociscan at The London Clinic, and the potential benefits of our Nociscan technology. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
